TheranosticTrials.org

Clinical Trial · NCT07835906

68Ga-NYM215 in NENs

Overview

This prospective study will evaluate the safety, biodistribution, dosimetry, and imaging performance of 68Ga-NYM215 PET/CT in patients with neuroendocrine neoplasms. An head-to-head comparison with 68Ga-DOTATATE PET/CT will assess the diagnostic performance of 68Ga-NYM215 PET/CT at both the patient and lesion levels.

Sponsor

Peking Union Medical College Hospital

Phase

Phase 1/2

Contacts

Meixi Liu, MD (CONTACT)

meixiliu_pumc@126.com

+86-15010405355

Huo Li, MD (CONTACT)

huoli@pumch.cn

+86-13910801986

ClinicalTrials.gov

NCT07835906

Drug / Compound

NYM215

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides

DOTATATE

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • At least one suspected lesion based on other imaging findings or clinical assessment.
  • Histopathologically confirmed neuroendocrine tumor.

Exclusion

  • Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR#30ml/min).
  • Inability to undergo PET/CT imaging.
  • Combined with other types of tumors.